DMH-1
Based on 15 publication(s) in Google Scholar
DMH-1 is a selective BMP inhibitor. DMH-1 upregulates the expression of SOX1. DMH-1 increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.93%
- CAS. Nr.: 1206711-16-1
- Formel: C24H20N4O
- Molecular Weight:380.44
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) DMH-1
More- Nat Immunol. 2025 Oct;26(10):1660-1672. [Abstract]
- Nat Commun. 2025 Sep 30;16(1):8693. [Abstract]
- Compos B Eng. 2023 Apr 6, 110711.
- Dev Cell. 2016 Oct 24;39(2):239-253. [Abstract]
- Stem Cell Res Ther. 2022 Sep 2;13(1):436. [Abstract]
- J Genet Genomics. 2022 Dec;49(12):1101-1113. [Abstract]
- Cell Rep. 2019 Feb 12;26(7):1709-1717.e3. [Abstract]
- Ecotoxicol Environ Saf. 2025 Mar 21:294:118068. [Abstract]
- Cell Prolif. 2024 Apr 16:e13646. [Abstract]
- Cell Prolif. 2024 Apr;57(4):e13577. [Abstract]
- Respir Res. 2026 Feb 28;27(1):109. [Abstract]
- Neuropharmacology. 2025 Apr 16:110469. [Abstract]
- Development. 2017 Nov 1;144(21):3894-3906. [Abstract]
- SSRN. 2025 Jul 25.
- Technical University of Munich. 2015 Jun.
-
RT-PCR
-
In Vivo Efficacy Study
-
WB
Biologische Aktivität
DMH-1 (0.5 μM) induces the formation of beating embryoid bodies (EBs), with an efficiency of approximately 20% on day 7, peaking at approximately 75% on day 9. Its efficiency at all evaluated time points is significantly higher than that of the DMSO control group[1].
DMH-1 (0.5 μM) specifically upregulates the expression profile of canonical cardiogenic genes, including BryT, Mesp1, Isl1 and Nkx2.5, and does not significantly induce the expression of non-cardiomyocyte mesodermal, endodermal or ectodermal markers compared with the DMSO control group[1].
DMH-1 (0.5 μM; 24-48 h) does not induce cell apoptosis[1].
DMH-1 (0.5-10 μM; 7 days) increases the expression of SOX1 in hiPSCs in a concentration-dependent manner[2].
DMH-1 (0.5 μM) induces hiPSC-derived neural progenitor cells to differentiate into β3-tubulin-positive neurons[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CGR8 mouse embryonic stem cell-derived EBs
-
Concentration:0.5 μM
-
Incubation Time:from induction, assessed at Day 3, Day 4, Day 6, Day 8, Day 10
-
Result:Significantly upregulated pre-mesoderm marker BryT (Day 3, Day 4), mesoderm lineage marker Mesp1 (Day 3, Day 4), second heart field marker Isl1 (Day 3, Day 4), and cardiomyocyte-specific marker Nkx2.5 (Day 6, Day 8, Day 10) relative to DMSO vehicle control.
Did not specifically induce hematopoietic marker Gata1, multipotent progenitor marker Kdr/Flk-1, smooth muscle marker Myh11, endoderm markers Sox17 or FoxA2, or ectoderm marker Nestin relative to DMSO vehicle control.
Induced a modest 2.3-fold increase in endocardial marker VE-CAM on Day 10 relative to DMSO.
Chemical Information
-
CAS. Nr. 1206711-16-1
-
Appearance Solid
-
Molecular Weight 380.44
-
Formel C24H20N4O
-
Color Off-white to yellow
-
SMILES
CC(C)OC1=CC=C(C2=CN3C(N=C2)=C(C4=CC=NC5=CC=CC=C45)C=N3)C=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Nat Immunol
Delaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response. [Abstract]2025 Oct;26(10):1660-1672. PMID: 40954252 -
Nat Commun
Geometrically-engineered human motor assembloids-on-a-chip for neuromuscular interaction readout and hypoxia-driven disease modeling. [Abstract]2025 Sep 30;16(1):8693. PMID: 41028715 -
-
Dev Cell
Tbx2 and Tbx3 Act Downstream of Shh to Maintain Canonical Wnt Signaling during Branching Morphogenesis of the Murine Lung. [Abstract]2016 Oct 24;39(2):239-253. PMID: 27720610 -
Stem Cell Res Ther
Stable expression of a truncated TLX variant drives differentiation of induced pluripotent stem cells into self-renewing neural stem cells for production of extracellular vesicles. [Abstract]2022 Sep 2;13(1):436. PMID: 36056423 -
J Genet Genomics
Cdx1b protects intestinal cell fate by repressing signaling networks for liver specification. [Abstract]2022 Dec;49(12):1101-1113. PMID: 36460297
DMH-1 purchased from MedChemExpress. Usage Cited in: J Genet Genomics. 2022 Dec;49(12):1101-1113. [Abstract]
The mitigation effect of Bmp inhibitor DMH1(5 mM; 2 days) on the hepatized intestine phenotype is dosage dependent. Left, representative WISH images; right, the intestine versus liver ratio of the fabp10a signals in cdx1bzju1/zju1. Embryos were treated with inhibitors starting from 36 hpf, respectively, and were subjected to WISH at 5 dpf with the fabp10a probe. Each spot represented one embryo.
-
Cell Rep
2019 Feb 12;26(7):1709-1717.e3. PMID: 30759383 -
Ecotoxicol Environ Saf
Melatonin mediates the BMP4/MAPK signaling pathway to alleviate zearalenone-induced abnormal embryonic development in mice. [Abstract]2025 Mar 21:294:118068. PMID: 40120487 -
Cell Prolif
Deletion of Tgm2 suppresses BMP-mediated hepatocyte-to-cholangiocyte metaplasia in ductular reaction. [Abstract]2024 Apr 16:e13646. PMID: 38623945
DMH-1 purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2024 Apr 16:e13646. [Abstract]
DMH-1 (5 mg/kg; i.p.; every other day for 3 weeks ). Hepatic expression levels of ID1, OPN, and SSTR2 in Tgm2CreERT2‐R26T/Gf/f mouse liver (n ≥ 4/group).
-
Cell Prolif
NAT10-mediated ac4 C modification promotes ectoderm differentiation of human embryonic stem cells via acetylating NR2F1 mRNA. [Abstract]2024 Apr;57(4):e13577. PMID: 38041497 -
Respir Res
CRISPR/Cas9-mediated B2m knockout paves the way for allogeneic basal cell transplantation. [Abstract]2026 Feb 28;27(1):109. PMID: 41764471 -
Neuropharmacology
ACVR1 drives neuropathic pain by regulating NLRP3-Induced neuronal pyroptosis through the p38 and Smad1/5/8 pathways. [Abstract]2025 Apr 16:110469. PMID: 40250754 -
Development
Anteroposterior polarity and elongation in the absence of extra-embryonic tissues and of spatially localised signalling in gastruloids: mammalian embryonic organoids. [Abstract]2017 Nov 1;144(21):3894-3906. PMID: 28951435 -
-
DMH-1 purchased from MedChemExpress. Usage Cited in: Technical University of Munich. 2015 Jun.
Western blot analysis of MPC cells treated with DMH1. MPC cells are treated with DMH1 (3 μM or 5 μM) or with DMSO vehicle for 48 h. Proteins are then collected and probed for the expression of integrin β1, P-Smad1/5/8, P-S6 (1:500) and α-Tubulin is used as a loading control. Numbers below AKT and S6 represent the quantification of band intensities of P-AKT to AKT (OD P-AKT/ AKT) and P-S6 to S6 (OD PS6/S6) to determine the activity of the proteins.
Lösungsmittel & Löslichkeit
DMSO : 11.5 mg/mL (30.23 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.63 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Ao A, et al. DMH1, a novel BMP small molecule inhibitor, increases cardiomyocyte progenitors and promotes cardiac differentiation in mouse embryonic stem cells. PLoS One. 2012;7(7):e41627. [Content Brief]
[2]. Neely MD, et al. DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. ACS Chem Neurosci. 2012;3(6):482-491. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6285 mL | 13.1427 mL | 26.2854 mL | 65.7134 mL |
| 5 mM | 0.5257 mL | 2.6285 mL | 5.2571 mL | 13.1427 mL | |
| 10 mM | 0.2629 mL | 1.3143 mL | 2.6285 mL | 6.5713 mL | |
| 15 mM | 0.1752 mL | 0.8762 mL | 1.7524 mL | 4.3809 mL | |
| 20 mM | 0.1314 mL | 0.6571 mL | 1.3143 mL | 3.2857 mL | |
| 25 mM | 0.1051 mL | 0.5257 mL | 1.0514 mL | 2.6285 mL | |
| 30 mM | 0.0876 mL | 0.4381 mL | 0.8762 mL | 2.1904 mL |